Health Law Alliance, under Anthony Mahajan's leadership, celebrates favorable outcomes in federal and state cases involving inventory shortfalls, showcasing their expertise in PBM audit defense. Successful dismissals of criminal charges and reduced civil settlements highlight Health Law Alliance's strategic approach in resolving cases stemming from PBM audits.

Health Law Alliance is pleased to announce the successful resolution of numerous federal and state cases involving significant inventory shortfalls, including the dismissal of criminal charges and civil settlements for fractions of the dollar amount on claims paid.

Pharmacy Inventory

As discussed below, Health Law Alliance (HLA)’s attorneys specialize in the defense of PBM audits and inventory discrepancies. We could not be more pleased to obtain the outcomes discussed below on behalf of clients.

PBM Audit Case Study #1

Commonwealth of Massachusetts v. Pharmacy & Owner. Following a PBM audit that noted significant inventory discrepancies, the State of Massachusetts Attorney General's Office opened an investigation.

After a lengthy investigation, Owner and pharmacy were both indicted and charged with criminal offenses that carried penalties involving lengthy prison sentences and exclusion. The 14-count indictments alleged that Owner billed Medicaid and other insurance plans almost $500,000 for 37,000 units of Zegerid, a heartburn medicine, even though the pharmacy's records indicated that the pharmacy had only purchased 12,000 units, a discrepancy of 25,000 units.

In addition, the indictments charged Owner with crimes relating to the dispensing of controlled substances, including accepting cash for prescriptions covered by MassHealth.

Following the criminal charges, the HLA team determined that the best strategy was to win in court, and pushed for an immediate trial. As a result of HLA's work, the Attorney General's Office dismissed all 14 counts in both indictments completely, permitted the pharmacy to remain in network, and did not exclude Owner.

PBM Audit Case Study #2

United States v. Pharmacy & Owner: Following PBM audits that noted inventory discrepancies, the U.S. Attorney's Office for the Eastern District of Pennsylvania, DEA and HHS-OIG opened an investigation.

After a review of the evidence, federal prosecutors alleged that Owner and his pharmacies had billed Medicare for approximately $6.5 million in compound creams across multiple pharmacies even though the pharmacy’s records indicated that they had never purchased the APIs in those creams.

In addition, the government alleged that Owner had violated laws relating to controlled substances, including Schedule II substances.

Following these threatened charges, the HLA team determined that the best strategy was to convince federal prosecutors not to file criminal charges and resolve the case. As a result of HLA's work, Owner was not charged criminally and instead settled the matter civilly for $2.5 million (62% less than the alleged discrepancy), admitted no wrongdoing, and was not excluded.

PBM Audit Case Study #3

Commonwealth of Pennsylvania v. Pharmacy & Owner: Following PBM audits that noted inventory discrepancies, the State of Pennsylvania Attorney General's Office opened an investigation.

After a lengthy investigation, the Attorney General moved to indict both the pharmacy and Owner on criminal felony charges for billing Medicaid nearly $600,000 for dispensing medications that were never provided to customers, either because the pharmacy never had them in stock or had sold them to another company for financial gain.

After analyzing the case, our HLA team determined that the best strategy was to negotiate the most favorable resolution possible. As a result of HLA's work, the Attorney General's Office declined prosecution of Owner, a particularly noteworthy accomplishment given his citizenship status.

Instead, as part of the settlement, the Attorney General's Office agreed to charge the corporate entity, which permitted Owner to avoid criminal charges and exclusion. Happily, Owner now can look forward to a life in this country with his family.

HLA Specializes in PBM Audit Defense

Finally, please note that the above cases are public matters, and HLA cannot discuss the numerous other inventory cases that have been resolved successfully before they became public. Here, at the Health Law Alliance, our firm’s mission is simple: use unmatched experience and insight to defend our clients against insurance conglomerates, the federal government, and state agencies. We used to work for them. Now let us fight for you. Contact us today for a consultation. We can help.

Frequently Asked Questions

Pharmacy Benefit Managers (PBMs) Face Possible FTC Lawsuit

The Federal Trade Commission (FTC) plans to sue the top Pharmacy Benefit Managers (PBMs) for anti-competitive practices, including influencing drug prices and favoring their own networks, which disadvantage independent pharmacies and raise prescription drug costs.

Read More >>

Victories Against Optum Rx: Protecting Pharmacy Clients Nationwide

Health Law Alliance has successfully challenged Optum Rx's termination decisions for numerous pharmacies, ensuring they can continue to operate and serve their communities. These victories highlight the firm's expertise in healthcare law and its dedication to protecting pharmacy clients from unjust PBM actions.

Read More >>

FTC Issues Interim Report Condemning Anticompetitive PBM Practices

The top Pharmacy Benefit Managers (PBMs) are condemned by the FTC for manipulating the healthcare system to generate significant profits, thereby inflating drug costs and overcharging patients, particularly for critical medications like cancer drugs.

Read More >>

Seized Ozempic Shipments Highlight Rising Demand and Safety Concerns

Ozempic, a well-known medication for type 2 diabetes, has gained popularity for its off-label use in weight loss, leading to increased scrutiny by authorities. Recently, U.S. Customs and Border Protection (CBP) officers in Cincinnati seized several shipments of the drug, underscoring the growing demand and associated risks.

Read More >>